GoodRx Reveals Americans Overspent on Weight Loss Medications by $200 Million This Year, Fills Still Surged
GoodRx has released a new Weight Loss Medications Tracker revealing significant trends in medication usage and spending. Despite insurance coverage and high costs, fill rates for weight loss drugs have surged dramatically in 2024, with Wegovy increasing by 100% and Zepbound by 300%. The research shows Americans overspent by $200 million in 2024 by paying full retail prices instead of using available savings.
Insurance coverage remains , with only 9% of people having unrestricted coverage for Zepbound and 14% for Wegovy. Even with insurance, patients face high out-of-pocket costs, averaging over $2,500 annually for Zepbound. Regional disparities show Alaska leading in overall fill rates, while Massachusetts, New Jersey, Rhode Island, and Delaware show higher rates for specific weight loss medications.
GoodRx ha rilasciato un nuovo Tracker sui Farmaci per la Perdita di Peso che rivela tendenze significative nell'uso e nella spesa per i farmaci. Nonostante la copertura assicurativa e i costi elevati, i tassi di prescrizione per i farmaci per la perdita di peso sono aumentati drasticamente nel 2024, con un aumento del 100% per Wegovy e del 300% per Zepbound. La ricerca mostra che gli americani hanno speso in eccesso 200 milioni di dollari nel 2024, pagando i prezzi al dettaglio completi invece di utilizzare i risparmi disponibili.
La copertura assicurativa rimane limitata, con solo il 9% delle persone che ha una copertura illimitata per Zepbound e il 14% per Wegovy. Anche con l'assicurazione, i pazienti affrontano costi elevati, con una media di oltre 2.500 dollari all'anno per Zepbound. Le disparità regionali mostrano l'Alaska in testa per tassi di prescrizione complessivi, mentre Massachusetts, New Jersey, Rhode Island e Delaware mostrano tassi più elevati per farmaci specifici per la perdita di peso.
GoodRx ha lanzado un nuevo Rastreador de Medicamentos para la Pérdida de Peso que revela tendencias significativas en el uso y el gasto en medicamentos. A pesar de la cobertura del seguro y los altos costos, las tasas de prescripción para los medicamentos para la pérdida de peso han aumentado drásticamente en 2024, con un aumento del 100% para Wegovy y del 300% para Zepbound. La investigación muestra que los estadounidenses gastaron en exceso 200 millones de dólares en 2024, pagando precios al por menor en lugar de utilizar los ahorros disponibles.
La cobertura del seguro sigue siendo limitada, con solo el 9% de las personas que tiene cobertura ilimitada para Zepbound y el 14% para Wegovy. Incluso con el seguro, los pacientes enfrentan altos costos de bolsillo, con un promedio de más de 2,500 dólares anuales para Zepbound. Las disparidades regionales muestran que Alaska lidera en tasas de prescripción general, mientras que Massachusetts, Nueva Jersey, Rhode Island y Delaware muestran tasas más altas para medicamentos específicos para la pérdida de peso.
GoodRx가 새로운 체중 감량 약물 추적기를 발표하여 약물 사용과 지출의 중요한 트렌드를 드러냈습니다. 보험 적용과 높은 비용에도 불구하고 체중 감량 약물의 처방률은 2024년에 크게 증가했습니다. Wegovy는 100% 증가했고, Zepbound는 300% 증가했습니다. 연구에 따르면 미국인들은 2024년에 이용할 수 있는 절감 혜택을 사용하지 않고 정가를 지불하여 2억 달러를 초과 지출했습니다.
보험 적용은 여전히 제한적이며, 9%의 사람만이 Zepbound에 대한 무제한 보험을 가지고 있고, 14%가 Wegovy에 대한 무제한 보험을 가지고 있습니다. 보험이 있어도 환자들은 Zepbound에 대해 연평균 2,500 달러 이상의 높은 본인 부담 비용을 겪고 있습니다. 지역별 차이를 살펴보면 알래스카가 전체 처방률에서 선두를 달리고 있으며, 매사추세츠, 뉴저지, 로드아일랜드, 델라웨어가 특정 체중 감량 약물에 대해 더 높은 비율을 보이고 있습니다.
GoodRx a publié un nouveau Suivi des Médicaments pour la Perte de Poids révélant des tendances significatives dans l'utilisation et les dépenses en médicaments. Malgré la couverture d'assurance et les coûts élevés, les taux de prescription pour les médicaments de perte de poids ont augmenté de manière spectaculaire en 2024, avec Wegovy en hausse de 100% et Zepbound de 300%. La recherche montre que les Américains ont dépensé 200 millions de dollars en trop en 2024 en payant des prix de détail complets au lieu d'utiliser les économies disponibles.
La couverture d'assurance reste limitée, avec seulement 9% des personnes ayant une couverture illimitée pour Zepbound et 14% pour Wegovy. Même avec l'assurance, les patients font face à des coûts élevés de leur poche, avec une moyenne de plus de 2 500 dollars par an pour Zepbound. Les disparités régionales montrent que l'Alaska est en tête des taux de prescription globaux, tandis que le Massachusetts, le New Jersey, le Rhode Island et le Delaware affichent des taux plus élevés pour des médicaments spécifiques de perte de poids.
GoodRx hat einen neuen Tracker für Gewichtsreduktionsmedikamente veröffentlicht, der bedeutende Trends in der Nutzung und den Ausgaben für Medikamente aufzeigt. Trotz der Krankenversicherungsdeckung und hoher Kosten sind die Verschreibungsraten für Gewichtsreduktionsmedikamente im Jahr 2024 drastisch gestiegen, wobei Wegovy um 100% und Zepbound um 300% zugenommen hat. Die Forschung zeigt, dass die Amerikaner im Jahr 2024 200 Millionen Dollar zu viel ausgegeben haben, indem sie die vollen Einzelhandelspreise bezahlt haben, anstatt die verfügbaren Einsparungen zu nutzen.
Die Versicherung bleibt begrenzt, da nur 9% der Menschen eine uneingeschränkte Deckung für Zepbound und 14% für Wegovy haben. Selbst mit Versicherung haben die Patienten hohe Selbstkosten, die im Durchschnitt über 2.500 Dollar jährlich für Zepbound liegen. Regionale Unterschiede zeigen, dass Alaska bei den Gesamtverschreibungsraten führend ist, während Massachusetts, New Jersey, Rhode Island und Delaware höhere Raten für bestimmte Medikamente zur Gewichtsreduktion aufweisen.
- Fill rates for weight loss medications showing strong growth (Wegovy +100%, Zepbound +300%)
- Company identifies $200 million in potential savings opportunity for consumers
- Wide pharmacy network coverage (70,000+ locations)
- insurance coverage affecting medication accessibility (only 9% unrestricted coverage for Zepbound, 14% for Wegovy)
- High out-of-pocket costs ($2,500+ annually for Zepbound with insurance)
Insights
In 2024, fills for Wegovy and Zepbound increased by over
Highlights from the new research include:
-
Surging fill rates: Even as patients grapple with high costs and limited insurance coverage, demand for weight loss medications is skyrocketing. Since the start of 2024, fills for Wegovy and Zepbound increased by
100% and300% , respectively. -
Limited insurance coverage: Despite growing interest and proven health benefits, GIP and GLP-1 agonists are still not widely covered by insurance when prescribed specifically for weight loss. In fact, nearly 1 in 5 people with commercial insurance have no coverage of GIP and GLP-1 agonists prescribed for weight loss at all. For example, only
9% of people with commercial insurance have unrestricted coverage of Zepbound and just14% have unrestricted coverage of Wegovy. Even with insurance coverage, out-of-pocket costs are still high with the average person taking Zepbound paying over$2,500 -
Regional disparities: Some states see higher use of weight loss medications than others. Surprisingly,
Alaska leads the nation with the highest overall fill rate for weight loss medications.Massachusetts ,New Jersey ,Rhode Island , andDelaware see higher rates for medications specifically targeting weight loss, such as Wegovy, Zepbound, Saxenda, Qsymia, and phentermine.
“GLP-1 and GIP medications have proven extremely effective in helping reduce and manage weight in overweight individuals, yet many health insurance plans lack necessary coverage and create cost barriers for many people in need, ” says Tori Marsh, MPH, Director of Research at GoodRx. “Our latest findings reveal that Americans overspent by hundreds of millions on these essential treatments in 2024 alone. At GoodRx, we’re committed to bridging this gap by offering significant savings, ensuring that more people can afford their necessary medications.”
GoodRx Can Help You Save
Before spending money out of pocket, consumers should check GoodRx to find ways to save on popular weight loss medications. Patients can save an average of
In addition to GLP-1’s, GoodRx recently announced a deal with VIVUS for its oral weight-loss medication QSYMIA® to offer consumers an exclusive low cash price at more than 70,000 retail pharmacy locations nationwide.
Learn More From Trusted Doctors, Pharmacists & Health Experts
Weight loss medications can be expensive and hard to understand. To help support consumers on their weight loss journeys, GoodRx offers credible, timely and actionable information to help people learn more about the process, get information about common concerns, uncover treatment options, and access significant savings. Each article is researched and written by a team of editorial experts, and clinical content is written and reviewed by a team of medical experts that includes physicians, pharmacists, and more.
To find savings and trusted health information, go to www.goodrx.com/glp-1-discounts
About GoodRx
GoodRx is the leading prescription savings platform in the
GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.
GoodRx Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated consumer savings and accessibility; and the objectives and potential benefits and value of the GoodRx research and savings. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause GoodRx’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to GoodRx’s ability to achieve broad market education and change consumer purchasing habits, changes in medication pricing and pricing structures, GoodRx’s reliance on a limited number of industry participants, and the important factors discussed in the section entitled “Risk Factors” in GoodRx’s Annual Report on Form 10-K for the year ended December 31, 2023, and GoodRx’s other filings with the Securities and Exchange Commission. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While GoodRx may elect to update such forward-looking statements at some point in the future, GoodRx disclaims any obligation to do so, even if subsequent events cause GoodRx’s views to change.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205403452/en/
Media Contact
press@goodrx.com
Source: GoodRx
FAQ
What was the increase in Wegovy and Zepbound fills in 2024 according to GoodRx (GDRX)?
How much did Americans overspend on weight loss medications in 2024 according to GoodRx (GDRX)?
What percentage of people with commercial insurance have unrestricted coverage for Zepbound and Wegovy according to GoodRx (GDRX)?
